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OM-85 is an immunomodulator 
of interferon-β production and 
inflammasome activity
A. T. Dang1, C. Pasquali2, K. Ludigs1,† & G. Guarda1
The inflammasome–IL-1 axis and type I interferons (IFNs) have been shown to exert protective effects 
upon respiratory tract infections. Conversely, IL-1 has also been implicated in inflammatory airway 
pathologies such as asthma and chronic obstructive pulmonary disease (COPD). OM-85 is a bacterial 
extract with proved efficacy against COPD and recurrent respiratory tract infections, a cause of co-
morbidity in asthmatic patients. We therefore asked whether OM-85 affects the above-mentioned innate 
immune pathways. Here we show that OM-85 induced interferon-β through the Toll-like receptor adaptors 
Trif and MyD88 in bone marrow-derived dendritic cells. Moreover, it exerted a dual role on IL-1 production; 
on the one hand, it upregulated proIL-1β and proIL-1α levels in a MyD88-dependent manner without 
activating the inflammasome. On the other hand, it repressed IL-1β secretion induced by alum, a well-
known NLRP3 activator. In vivo, OM-85 diminished the recruitment of inflammatory cells in response to 
peritoneal alum challenge. Our findings therefore suggest that OM-85 favors a protective primed state, 
while dampening inflammasome activation in specific conditions. Taken together, these data bring 
new insights into the mechanisms of OM-85 action on innate immune pathways and suggest potential 
explanations for its efficacy in the treatment of virus-induced airway diseases.
Inflammatory airway diseases are an emerging health problem with high incidence in developed countries. Two 
important examples are chronic obstructive pulmonary disease (COPD) and asthma. Both disorders are char-
acterized by narrowing of the airways and by a strong inflammatory component1. Multiple mediators have been 
implicated in the development of these pathologies, as in particular T helper type (Th)2 cytokines1. However, 
significant alterations of innate immune cytokines have also been associated with these disorders. Asthmatic 
patients show decreased production of type I and III interferons (IFNs), which augments susceptibility to virally 
induced asthma exacerbations2–6. IFNs are important antiviral and immunomodulatory cytokines, promoting 
control of respiratory infections while reducing collateral damage and excessive inflammation2–12. In fact, viral 
infections early in life, but also at later stages, are increasingly recognized as predisposing or aggravating events 
of asthmatic manifestations13–15.
Interestingly, also several links between interleukin (IL)-1 and inflammatory airway diseases have been estab-
lished16,17. IL-1α and IL-1β are strong inflammatory cytokines, sharing the common IL-1 receptor. Whereas IL-1α 
does not require processing for activity, IL-1β is synthesized as a biologically inactive precursor, called proIL-1β , 
and requires cleavage by the protease caspase-1 to be converted into its active form18. The activation of caspase-1 
takes place within a protein complex known as “inflammasome”, which is formed by a nucleating sensor protein, 
an adaptor protein called apoptosis-associated speck-like protein containing a CARD (ASC), and caspase-118,19. 
Several receptors of the NOD-like receptor (NLR) family have been shown to assemble inflammasome platforms, 
including the intensively studied NLRP319,20. NLRP3 is well expressed and best studied in innate immune cells 
and senses a plethora of stimuli encompassing particulate stimuli, pore-forming toxins, and pathogens of fungal, 
bacterial, as well as viral origin18–21. In addition, AIM2, which is mainly expressed in immune cells, nucleates a 
well-characterized inflammasome upon recognition of cytoplasmic double-stranded DNA18,22.
These two sensors, are of particular interest with regard to antiviral and inflammatory reactions in the 
lung16,23–27. Upon influenza infection, NLRP3 inflammasome activation in lung dendritic cells (DCs) and mac-
rophages exerts a protective effect, whereas its overactivation contributes to severe pathophysiology23–27. Similarly, 
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in models of pulmonary fibrosis and silicosis, a detrimental role for the NLRP3/IL-1 axis was witnessed16,28–39. The 
overall contribution of inflammasome and IL-1 to airway pathologies remains therefore multifaceted, exerting 
protective effects in the context of viral infections, but also harmful ones in chronic inflammatory conditions.
From the medical standpoint, recurrent respiratory tract infections (RTIs), COPD, as well as wheezing and 
asthma are major public health problems. Concomitantly, prevalence of antibiotic resistance among common res-
piratory pathogens has recently risen, highlighting the need to develop strategies of immunization against respira-
tory bacteria and viruses40–42. Launched more than 30 years ago, OM-85 (Broncho-Vaxom® , Broncho-Munal® , 
Ommunal® , Paxoral® , Vaxoral® ), an oral medicine of biological origin used for the prevention of recurrent RTIs 
and/or exacerbations in at-risk populations, was shown to be effective and safe in both children and adults43–47. Its 
active principle, an extract of bacterial lysates isolated from 21 known respiratory pathogenic strains, showed pro-
tection against airway infections of bacterial and viral origin. In particular, several studies highlighted the capacity 
of OM-85 to trigger immunomodulatory and protective immune responses against diverse pathogens in vivo48–54, 
including influenza and respiratory syncytial virus as well bacterial superinfection following influenza55,56.
Despite these findings, the effects of OM-85 on the production of type I interferons or inflammasome-mediated 
IL-1 production have not been assessed. We thus dissected the role of OM-85 in regulating these pathways 
in vitro. We found that OM-85 induced IFN-β production and acted as an effective priming agent inducing sub-
stantial levels of proIL-1α and β . Surprisingly, OM-85 also interfered with inflammasome activity specifically in 
response to alum. These results suggest that OM-85 dampens selected inflammatory reactions, while potentiating 
innate immune defenses, two effects that might contribute to reducing infections and alleviating COPD and asth-
matic conditions in the context of the respiratory tract.
Results
OM-85 induces interferon-β production. Given the potential relevance of type I IFN in asthmatic 
patients, we investigated the ability of OM-85 to induce this cytokine. We focused on DCs, which are proficient 
in producing type I IFNs and in activating the inflammasome pathway21,25,26. We therefore treated bone mar-
row-derived DCs (BMDCs) for 16 hours and assessed IFN-β release in the supernatant. IFN-β production was 
detected and followed a bell-shaped curve as a function of OM-85 concentration (Fig. 1a). To gain insights into 
the OM-85-dependent mechanisms inducing IFN-β , we took advantage of Trif- and MyD88-deficient BMDCs. 
Interestingly, the absence of either Trif or MyD88 drastically affected OM-85-driven IFN-β production (Fig. 1b). 
Taken together, we show here that OM-85 has the ability to induce IFN-β production, an important cytokine 
playing immunomodulatory and antiviral effects, in a MyD88- and Trif-dependent manner.
OM-85 does per se not lead to IL-1 release. We next tested the effects of OM-85 on the inflammas-
ome/IL-1 axis. Given the complex nature of OM-85, we first asked whether this extract exhibited the capac-
ity to induce IL-1β and α production. This encompasses the steps of inducing their precursor forms, referred 
to as “priming”, and of activating the inflammasome for their cleavage and/or secretion. We therefore treated 
BMDCs with increasing doses of OM-85 for either 6 or 16 hours and measured the release of IL-1β and IL-1α 
by ELISA. As shown in Fig. 2a and b, no substantial production of these cytokines was observed as compared to 
the unstimulated condition, whereas they were nicely released upon standard two-step stimulation performed by 
LPS-mediated priming and the NLRP3 inflammasome activator aluminium (alum). This indicates that OM-85 
has not per se the capacity to induce the inflammasome/IL-1 cascade.
OM-85 acts as a priming signal mainly through MyD88. Despite the inability to induce IL-1 secretion, 
the bacterial origin of OM-85 suggested it to be able to act as a priming signal. We therefore tested its ability to 
prime BMDCs, which were then treated with alum. As shown in Fig. 3a and b, exposure to OM-85 effectively 
induced the production of IL-1β and IL-1α by alum-triggered BMDCs. We thus tested the induction of proIL-1β 
Figure 1. OM-85 promotes the production of type I IFN. (a and b) Wild type (WT) BMDCs were stimulated with 
the indicated doses of OM-85 (a) or Wild type (WT), Trif−/−, and MyD88−/− BMDCs were stimulated with 320 μ g/ml 
OM-85 (b) for 16 hours (h). IFN-β secretion was measured by ELISA. Results represent mean ± SD (n = 3 technical 
replicates) and are representative of at least four (a) and two (b) independent experiments. Statistical differences were 
calculated between the condition without OM-85 (0) and each of the following doses using Student’s t-test adjusted by 
Bonferroni correction over 5 (a) and between the wild type condition and the mutant genotypes using Student’s t-test 
adjusted by Bonferroni correction over 2 (b). ns, non-significant; ***p ≤ 0.001.
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and proIL-1α in BMDCs upon a four hours treatment with OM-85. As shown in Fig. 3c, the bacterial extract 
increased the amount of proIL-1α and proIL-1β in a dose-dependent manner.
Next, we used Trif- and MyD88-deficient BMDCs to understand whether these adaptor proteins mediated 
OM-85-induced proIL-1β and proIL-1α . Whereas the absence of Trif only slightly affected the levels of proIL-1α , 
MyD88 deficiency abolished OM-85-induced priming with regard to both proIL-1β and proIL-1α (Fig. 3c). These 
data indicate that OM-85 did not deploy toxic effects even at high concentrations and was active, modulating 
pro-IL-1β and α in a MyD88-dependent manner.
OM-85 acts as a priming signal for the NLRP3 and the AIM2 inflammasomes. We next asked 
whether OM-85 was an effective priming agent for multiple activators of the NLRP3 as well as for the AIM2 
inflammasome, as both these platforms are important for detection of and protection from viral infections. To 
address these questions, BMDCs pre-treated for four hours with different doses of OM-85 were exposed to the 
particulate NLRP3 activators alum and monosodium urate (MSU) crystals as well as to the soluble activators ATP 
and nigericin. As illustrated in Fig. 4a and b, OM-85 was an efficient priming signal for all of these stimuli. While 
the effects by OM-85 treatment were consistent in all experiments, it is important to mention that the activity of 
OM-85 on BMDC was subject to some variation, as illustrated here between panels 3a/b and 4a/b at the lower 
doses applied (e.g. 10 ug/ml).
In addition, we observed that OM-85 acted in the same way for the AIM2 inflammasome (Fig. 4c and d). 
Intriguingly however, BMDCs pre-treated with the highest tested dose of OM-85 showed reduced production of 
IL-1α and IL-1β upon polydA:dT-mediated activation.
OM-85 pre-treatment interferes with LPS and alum-induced inflammasome activation. The 
observation that high-dose OM-85 induced a decrease of AIM2-mediated IL-1α and IL-1β release prompted us 
to further explore potential dampening effects of OM-85 on inflammasome activity. We therefore performed a 
modified version of the inflammasome activation assay in which we pre-treated BMDCs overnight with OM-85 
and added LPS for four hours, followed by inflammasome activators. Whereas we did not observe significant 
inhibitory effects on IL-1α and IL-1β secretion upon inflammasome triggering by ATP, we found that IL-1β 
secretion induced by alum and – to a smaller extent by MSU – was downmodulated by OM-85 pre-treatment 
(Fig. 5a and Supplementary Figure 1a). However, secreted IL-1α was not substantially decreased, as shown in 
Fig. 5b. In order to explain the reduced release of IL-1β , we checked the levels of cleaved caspase-1. Interestingly, 
caspase-1 activation was decreased by overnight OM-85 pre-treatment (Fig. 5c and Supplementary Figure 1b). 
Taken together, these data suggests that OM-85 pre-treatment dampens IL-1β production, at least partly through 
reducing inflammasome activity in response to alum.
Alum-driven peritonitis is reduced by OM-85. Based on the previous finding, we then tested whether 
the immunomodulatory effects of OM-85 on the inflammasome were recapitulated in an in vivo model. We 
focused on the well-established alum-dependent peritonitis model, which is mediated by IL-1α and IL-1β and is 
commonly used to assess inflammasome activity in vivo19. Wild type mice were pre-treated intravenously with 
OM-85, or PBS as control and, five hours later, injected intraperitoneally (i.p.) with alum. Twelve hours post 
alum-injection, mice were sacrificed and peritoneal exudate cells analyzed by flow cytometry. As depicted in 
Fig. 6a, a remarkable decrease in the numbers of recruited cells was observed. In addition, when specifically 
assessing the abundance of individual inflammatory subsets, a significant decrease in the numbers of neutrophils, 
eosinophils, as well as macrophages was observed (Fig. 6b–d). These data indicate that OM-85 has the ability of 
interfering also in vivo with alum-induced inflammatory reactions.
Figure 2. OM-85 does not activate the inflammasome. (a and b) Dose-response and time course (6 and 16 h) for 
the release of IL-1β (a) and IL-1α (b) by BMDCs in response to the indicated concentrations of OM-85 as measured 
by ELISA. As control, stimulation was performed with LPS (100 ng/ml) for 6 and 16 h or LPS (100 ng/ml) followed 
by addition of alum (300 μ g/ml) for the last 2.5 h. Results represent mean ± SD (n = 3 technical replicates) and are 
representative of two independent experiments. us = unstimulated (a and b). Statistical differences were calculated 
between the unstimulated condition and the other conditions by Student’s t-test adjusted by Bonferroni correction 
over 6 (a and b). nd, non-detected; ns, non-significant; **p ≤ 0.01; ***p ≤ 0.001.
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Discussion
Here we have provided evidence for the immunomodulatory effects of OM-85 on the production of two cytokines 
playing key roles in lung infections and diseases: type I interferons and IL-1. We found that OM-85 was able to 
induce IFN-β at an optimal intermediate concentration but less at higher doses. Interestingly, these data are remi-
niscent of results obtained with other inducers of type I IFNs, including DNA, RNA, and fungal pathogen-derived 
molecular patterns, which show a bell-shaped dose-response curve57–60. These findings suggested that 
OM-85-triggered IFN production was compatible with TLR stimulation, a hypothesis that was corroborated 
by the dependency on both TLR adaptor proteins Trif and MyD88. The ability of OM-85 to induce type I 
IFN was also observed – to a smaller extent – in human DCs61. This represents an important feature potentially 
involved in the beneficial effects of OM-85 in airway inflammatory diseases, as IFN is a well-known antiviral 
cytokine, contributing to minimize the occurrence of various respiratory tract infections and the subsequent 
exacerbations of chronic inflammatory conditions62,63.
Whereas OM-85 did not activate the inflammasome per se, it nicely primed BMDCs, significantly rising 
proIL-1α and proIL-1β levels, in agreement with data in human DCs61. Furthermore, our results showed that 
MyD88 was necessary to augment the levels of proIL-1α and proIL-1β , which are canonical NF-κ B targets, down-
stream of OM-85. Along these lines, previous findings showed a central role for TLRs, MyD88, and activation of 
downstream NF-κ B signaling by OM-8548,51,61. In addition, we show here the involvement of the adaptors MyD88 
and Trif in the induction of type I IFN, inferring the implication of TLR3 or TLR4 upon OM-85 treatment51.
In this work we focused on two inflammasome platforms relevant in the context of antiviral responses, 
and, in particular, of airway infections: AIM2 and NLRP316,23–27. We showed that OM-85 exposure efficiently 
pre-activated BMDCs, an effect that was also demonstrated for proIL-1β transcript level on human DCs, for sub-
sequent inflammasome activation and IL-1 production61. Given the role of the NLRP3 inflammasome and recent 
data proving the efficacy of OM-85 in controlling influenza infection, it is conceivable that part of the protective 
effect of OM-85 is mediated by priming of the inflammasome–IL-1 axis16,23–27,56. Our results indicate therefore 
that OM-85 treatment keeps innate immune cells in an “alerted state” ideal to release large amounts of IL-1 upon 
sensing an inflammasome trigger and, conceivably, to reduce selected viral infections.
Yet, the pre-activated state induced by OM-85 in BMDCs is not “inflammatory” per se, as negligible release 
of IL-1 is measured under these conditions. This is an important aspect when considering the detrimental effects 
of IL-1 on chronic inflammatory diseases1. It therefore seems that OM-85 has the ability to boost inflammation, 
but exclusively when specific activators of the inflammasome are present. Interestingly, we noticed that the effects 
of OM-85 on priming, particularly at low doses, diverged in response to different inflammasome activators. In 
general, activators inducing lower levels of IL-1 release, such as alum, required higher doses of OM-85, indicating 
a stronger dependency on priming.
Interestingly, we also observed that an overnight pre-treatment with OM-85 dampened the release of IL-1β 
induced by canonical LPS and alum stimulation. This inhibitory activity was in part due to a reduced activa-
tion of caspase-1. These in vitro results were corroborated by in vivo data showing that OM-85 pre-treatment 
Figure 3. OM-85 is a priming signal for alum-dependent inflammasome activation. (a and b) BMDCs 
were primed with 10 ng/ml LPS or the indicated doses of OM-85 for 4 h, followed by inflammasome activation 
with alum (300 μ g/ml) for 2.5 h. Release of IL-1β (a) and IL-1α (b) was measured by ELISA. Results represent 
mean ± SD (n = 3 technical replicates) and are representative of at least four independent experiments (a and b). 
Statistical differences were calculated between the LPS only condition and the other conditions by Student’s 
t-test adjusted by Bonferroni correction over 5 (a and b). nd, non-detected; ns, non-significant; *p ≤ 0.05; 
**p ≤ 0.01; ***p ≤ 0.001. Wild type (WT), Trif−/−, and MyD88−/− (c) BMDCs were primed with 10 ng/ml LPS or 
the indicated doses of OM-85 for 4 h. Levels of proIL-1β , proIL-1α , pro-caspase 1, and tubulin as control, were 
assessed in cell extracts by immunoblot analysis. Results are representative of two (c) independent experiments. 
us = unstimulated.
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substantially interferes with an IL-1-driven peritonitis model. It is important to stress that in vivo i.p. treatment 
with alum is sufficient for the secretion of IL-1α and IL-1β, indicating that their precursor proteins are synthe-
sized in response to endogenous priming stimuli. As we showed, OM-85 was per se able to pre-activate BMDCs 
for inflammasome activation and IL-1 production, suggesting therefore that its immunomodulatory nature ren-
ders it activatory in the absence of additional priming signals and – to some extent – inhibitory in their presence. 
It was however surprising to see that this effect was quite specific to alum and observed upon activation by MSU 
only when OM-85 was used at very high doses. This indicates that, besides clear differences between soluble and 
particulate activators32, more subtle distinctions exists among the latters, which might reside in their chemical or 
physical properties, including their size.
Despite a significant body of literature demonstrating that the inflammasome pathway exerts multiple and 
important functions in the pathophysiology of airway diseases, whether OM-85 regulates such cellular responses 
remained unanswered. Derived from common human bacterial respiratory tract pathogens and used for the pre-
vention of airway infections and chronic inflammation, OM-85 exhibits the capacity to modulate inflammasome 
responses. Our data suggest that the mode of action of OM-85 with regard to the IL-1 pathway is twofold. On the 
one hand, it dampens IL-1β production in response to alum. This effect might be important to prevent selected 
inflammatory reactions also in the lung, where OM-85 was previously shown to reduce inflammation48. On the 
other hand, OM-85 clearly supports adequate IL-1 production in the case of inflammasome activation. This effect 
might contribute to the protective effects of OM-85 in the presence of viruses controlled by the inflammasome56.
Experimental procedures
Immunoblot analysis. The antibody against mouse IL-1β was a gift from R. Solari (Imperial College, 
London), whereas the antibody against mouse caspase-1 was a gift from P. Vandenabeele (Ghent University, 
Belgium)64,65. Other antibodies used were monoclonal anti-tubulin from Sigma-Aldrich; rabbit polyclonal anti-
body to β -actin from Abcam; anti-IL-1α (ALF161) from ebioscience.
Figure 4. OM-85 is a priming signal for multiple inflammasomes. (a and b) BMDCs were primed with 
10 ng/ml LPS or the indicated doses of OM-85 (referring to μ g/ml) for 4 h, followed by stimulation with alum 
(300 μ g/ml), MSU (300 μ g/ml), nigericin, (0.1 μ M) for 2.5 h and ATP (500 μ M) for 45 min. Release of IL-1β and 
IL-1α was measured by ELISA. (c and d) BMDCs were primed as described above, followed by transfection of 
poly(dA:dT) (0.6 μg). 6 h after, release of IL-1β (c) and IL-1α (d) in the supernatants was measured by ELISA. 
Results represent mean ± SD (n = 3 technical replicates) and are representative of at least three (a and b) and 
two (c and d) independent experiments. us = unstimulated. Statistical differences were calculated between the 
condition exposed to the inflammasome activator only (Alum, MSU, ATP, or Nigericin in the absence of LPS) 
and the conditions treated with LPS or OM-85 and the inflammasome activator by Student’s t-test adjusted by 
Bonferroni correction over 4 (a and b). Statistical differences were calculated between the condition exposed 
to poly(dA:dT) in the absence of LPS and the conditions treated with LPS or OM-85 and poly(dA:dT) as well 
as between the condition treated by LPS and poly(dA:dT) and by OM-85 (1000 μ g/ml ) and poly(dA:dT) using 
Student’s t-test adjusted by Bonferroni correction over 5 (c and d). *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001.
www.nature.com/scientificreports/
6Scientific RepoRts | 7:43844 | DOI: 10.1038/srep43844
Mice. Six- to 12-wk-old C57BL/6, Trif−/−66, and MyD88−/−67 mice were housed at the animal facility of the 
University of Lausanne. All animal experimental protocols were approved by the Veterinary office regulations 
of the State of Vaud, Switzerland, and all methods were performed in accordance with the Swiss guidelines and 
regulations.
OM-85 formulation. OM-85 is produced at OM Pharma SA, Meyrin 1/Geneva, Switzerland. Bacteria are 
grown in individual batches, heat inactivated once they reach a critical mass, harvested, and then subject to 
alkaline lysis. After lysis, the lysates from the 21 different bacterial strains are mixed together, filtered, and the 
soluble fraction is neutralized. OM-85 active principle is an alkaline aqueous soluble extract obtained by micro-
filtration of the pooled 21 bacterial lysates of Haemophilus influenzae (1 strain), Streptococcus pneumoniae 
(4 strains), Klebsiella pneumoniae subsp. pneumoniae (2 strains), Klebsiella pneumoniae subsp. ozaenae 
(1 strains), Staphylococcus aureus (6 strains), Streptococcus pyogenes (1 strains), Streptococcus sanguinis 
(3 strains), Moraxella (Branhamella) catarrhalis (3 strains) with the following characteristics: 24 mg dry weight 
bacterial extract per mL. The oral formulation is the isotonic OM-85 bacterial extract neutralized at pH 7.0 using 
HCl 1 M.
In vitro stimulation experiments. BMDCs were differentiated as previously described68. For normal stim-
ulation experiments, 7 × 104 differentiated BMDCs were plated in DC differentiation medium (RPMI 1640, 10% 
FCS, 100 U/ml penicillin, 100 μ g/ml streptomycin, 50 μN 2-ME, 10 mM HEPES, supplemented with 20 ng/ml 
rGM-CSF (ImmunoTools)) and treated for the indicated times and with the indicated doses of OM-85 of 
Figure 5. OM-85 dampens IL-1β release induced by LPS priming and alum. (a–c) BMDCs were pre-treated 
overnight with the indicated doses of OM-85 (μ g/ml), primed with 10 ng/ml LPS for 4 h and then treated 
with 300 μ g/ml alum for 2.5 h. Release of IL-1β (a) and IL-1α (b) was measured by ELISA. Results represent 
mean ± SD (n = 3 technical replicates) (a and b). An illustration of all experiments performed is provided in 
Supplementary Figure 1a. (c) Levels of cleaved IL-1β and caspase 1 were assessed in culture supernatant by 
immunoblot analysis, whereas pro-IL-1β , pro-IL-1α , pro-caspase 1, and tubulin as control, were assessed in 
cell extracts. Results are representative of at least three independent experiments. Statistical significance was 
calculated between the condition treated with LPS and alum and the conditions pre-treated with various doses 
of OM-85 using Student’s t-test adjusted by Bonferroni correction over 4 (a,b). ns, non-significant; **p ≤ 0.01; 
***p ≤ 0.001.
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ultrapure LPS (Invivogen). For inflammasome activation experiments, 7 × 104 differentiated BMDCs were 
primed with 10 ng/ml ultrapure LPS or the indicated doses of OM-85 for the 4 h preceding inflammasome 
stimulations or left unprimed. Then, stimulations were carried out. ATP (500 μ M) and nigericin (0.1 μ M) were 
from Sigma, MSU crystals (300 μ g/ml) were from Adipogen, and alum (300 μ g/ml) from Pierce Biochemicals 
(Imject-alum). ATP stimulations were performed for 45 min and other stimulations for 150 min. For the stim-
ulation of the AIM2 inflammasome, poly(dA:dT) (purchased from Invivogen) was admixed at the indicated 
concentrations to Lipofectamine 2000 (from Invitrogen) according to manufacturer’s instructions and cells were 
stimulated for 6 h. For inflammasome inhibition experiments, 7 × 104 differentiated BMDCs were incubated for 
12 h or the indicated times in the presence of OM-85. Cells were then primed with 10 ng/ml ultrapure LPS for the 
4 h preceding inflammasome stimulations. Then, stimulations were carried out with the doses of inflammasome 
activators indicated in the text.
In vivo peritonitis experiments. For peritonitis, mice were injected i.v., with 2.5 mg OM85 followed 5 h 
later by an i.p. injection of 350 μ g alum (Pierce). 12–14 h after alum injection, mice were sacrificed and peritoneal 
cavities were washed with 6 ml PBS. PECs were counted and analyzed by flow cytometry using a combination 
of antibodies against CD11b (M1/70), Ly6C (AL-21), Ly6G (1A8) (BD Pharmingen), antiCD16/32 (93), CD11c 
(N418), F4/80 (BM8) (eBioscience). For cellular subtype analysis the following gating strategies were used: neu-
trophils (CD11b+, Ly6Ghigh, F4/80−), eosinophils (CD11b+, SSChigh) and macrophages (Ly6G−, SSClow, CD11b+, 
F4/80+), recruitment was analyzed on a FACSCanto (BD Bioscience) by using the FLOWJO software (Tree Star).
ELISA. Cell culture supernatants were assayed for mouse IL-1β , IL-1α (ebioscience), and IFN-β (PBL Assay 
Science) according to manufacturer’s instructions.
Statistical analysis. Statistical analyses were calculated as described in the Figure legends (GraphPad Prism 
version 5.0).
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